Literature DB >> 3370738

Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice.

T Matsuzaki1, T Yokokura, M Mutai, T Tsuruo.   

Abstract

The antimetastatic effect of a new water-soluble derivative of camptothecin, 7-ethyl-10-(4-(1-piperidino)-1-piperidino) carbonyloxy-camptothecin (CPT-11), were examined in several metastatic murine tumor systems. Intravenous (i.v.) injection of CPT-11 into BALB/c mice inhibited lung metastasis by i.v. inoculated, metastatic colonic adenocarcinoma 26 (C26) cells, C26NL-17, in BALB/c mice. This treatment was also effective in C57BL/6 mice against lung metastasis by i.v. inoculated B16-F10 and B16-BL6 cells, highly metastatic variants of the B16 melanoma. Furthermore, intraperitoneal (i.p.) injection of CPT-11 significantly inhibited the growth of C26NL-22 cells, a highly metastatic variant of C26, inoculated subcutaneously (s.c.) into the left front footpads of BALB/c mice. Also, i.p. or i.v. injection of CPT-11 effectively inhibited the growth of 3LL tumors inoculated s.c. into the hind footpads of C57BL/6 mice. Moreover, following s.c. inoculation of either C26NL-22 or 3LL cells, combined surgical excision of the primary tumor and either i.p. or i.v. CPT-11 injections given before or after surgery markedly inhibited the formation of pulmonary metastases. These results show that a new derivative of camptothecin, CPT-11, has a potent inhibitory effect against both spontaneous and experimental lung metastasis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3370738     DOI: 10.1007/bf00264196

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  15 in total

Review 1.  Camptothecin.

Authors:  M Shamma; V St Georgiev
Journal:  J Pharm Sci       Date:  1974-02       Impact factor: 3.534

Review 2.  Camptothecin.

Authors:  A G Schultz
Journal:  Chem Rev       Date:  1973-08       Impact factor: 60.622

3.  Prodrug analogues of the antitumor alkaloid camptothecin.

Authors:  J A Adamovics; C R Hutchinson
Journal:  J Med Chem       Date:  1979-03       Impact factor: 7.446

4.  The selection and characterization of an invasive variant of the B16 melanoma.

Authors:  I R Hart
Journal:  Am J Pathol       Date:  1979-12       Impact factor: 4.307

5.  Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin.

Authors:  R C Gallo; J Whang-Peng; R H Adamson
Journal:  J Natl Cancer Inst       Date:  1971-04       Impact factor: 13.506

6.  Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880).

Authors:  J A Gottlieb; A M Guarino; J B Call; V T Oliverio; J B Block
Journal:  Cancer Chemother Rep       Date:  1970-12

7.  Plant antitumor agents. 23. Synthesis and antileukemic activity of camptothecin analogues.

Authors:  M C Wani; A W Nicholas; M E Wall
Journal:  J Med Chem       Date:  1986-11       Impact factor: 7.446

8.  Characterization of metastatic clones derived from a metastatic variant of mouse colon adenocarcinoma 26.

Authors:  T Tsuruo; T Yamori; K Naganuma; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1983-11       Impact factor: 12.701

9.  Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogues.

Authors:  M C Wani; P E Ronman; J T Lindley; M E Wall
Journal:  J Med Chem       Date:  1980-05       Impact factor: 7.446

10.  Anti-tumor effect of (S)-10-hydroxycamptothecin on mouse hepatoma BW7756 and its possible mode of action.

Authors:  K C Tsou; B Xu; E E Miller; K W Lo
Journal:  Anticancer Res       Date:  1981       Impact factor: 2.480

View more
  16 in total

1.  A self-contained enzyme activating prodrug cytotherapy for preclinical melanoma.

Authors:  Gwi-Moon Seo; Raja Shekar Rachakatla; Sivasai Balivada; Marla Pyle; Tej B Shrestha; Matthew T Basel; Carl Myers; Hongwang Wang; Masaaki Tamura; Stefan H Bossmann; Deryl L Troyer
Journal:  Mol Biol Rep       Date:  2011-05-13       Impact factor: 2.316

2.  Metastasizing lung carcinomas in Hann: Wistar rats.

Authors:  K Kamino; M Kohler; U Mohr
Journal:  Clin Exp Metastasis       Date:  1992-07       Impact factor: 5.150

3.  The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation.

Authors:  J P Lamond; M P Mehta; D A Boothman
Journal:  J Neurooncol       Date:  1996-10       Impact factor: 4.130

4.  A cell-delivered and cell-activated SN38-dextran prodrug increases survival in a murine disseminated pancreatic cancer model.

Authors:  Matthew T Basel; Sivasai Balivada; Tej B Shrestha; Gwi-Moon Seo; Marla M Pyle; Masaaki Tamura; Stefan H Bossmann; Deryl L Troyer
Journal:  Small       Date:  2012-01-11       Impact factor: 13.281

5.  Limited sampling models for simultaneous estimation of the pharmacokinetics of irinotecan and its active metabolite SN-38.

Authors:  G G Chabot
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

6.  Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice.

Authors:  Y Kawato; T Furuta; M Aonuma; M Yasuoka; T Yokokura; K Matsumoto
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

7.  A risk-benefit assessment of irinotecan in solid tumours.

Authors:  L L Siu; E K Rowinsky
Journal:  Drug Saf       Date:  1998-06       Impact factor: 5.606

8.  Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.

Authors:  P J Houghton; P J Cheshire; J D Hallman; L Lutz; H S Friedman; M K Danks; J A Houghton
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

9.  Determinants of drug response in camptothecin-11-resistant glioma cell lines.

Authors:  Y Matsumoto; T Fujiwara; S Nagao
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

10.  Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer.

Authors:  N Masuda; M Fukuoka; S Kudoh; Y Kusunoki; K Matsui; N Takifuji; K Nakagawa; M Tamanoi; T Nitta; T Hirashima
Journal:  Br J Cancer       Date:  1993-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.